Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma
How to cite: Kuzuya, T.; Kawabe, N.; Muto, H.; Wada, Y.; Komura, G.; Nakano, T.; Tanaka, H.; Nakaoka, K.; Ohno, E.; Funasaka, K.; Nagasaka, M.; Miyahara, R.; Hirooka, Y. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Preprints 2024, 2024061981. https://doi.org/10.20944/preprints202406.1981.v1 Kuzuya, T.; Kawabe, N.; Muto, H.; Wada, Y.; Komura, G.; Nakano, T.; Tanaka, H.; Nakaoka, K.; Ohno, E.; Funasaka, K.; Nagasaka, M.; Miyahara, R.; Hirooka, Y. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Preprints 2024, 2024061981. https://doi.org/10.20944/preprints202406.1981.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)